Description of patients with elevated PGA and tender joint counts of 0 or 1 vs all BRASS patients at the 11th follow-up examination
| TJC/SJC both ≤1 and PGA ≥3 (n=49)* | All BRASS participants excluding study group (n=223) | |
| TJC (median/IQR) | 0 (0, 1) | 0 (0, 3) |
| SJC (median/IQR) | 0 (0, 1) | 0 (0, 2) |
| Patient Global Assessment (0–10) (median/IQR) | 5 (4, 6) | 1.5 (1, 5) |
| CRP in mg/dL (median/IQR) | 2.6 (1.0, 9.0) | 1.7 (0.8, 3.9) |
| DAS28 CRP score (median/IQR) | 2.03 (1.61, 2.32) | 2.18 (1.61, 2.97) |
| % on steroids | 24.5 | 29.3 |
| % on methotrexate | 49 | 52 |
| % on biologic agent | 67.4 | 64.6 |
| Age in years (median/IQR) | 65 (53, 73) | 66 (56, 72) |
| Sex (% women) | 85.7 | 83.9 |
| BMI (median/IQR) | 25.7 (22.4, 31.1) | 27 (23, 30.7) |
| Smoker (% current/% ever) | 2.3/59.2 | 2.1/38.6 |
| Race (% White) | 95.9 | 95.1 |
| Ethnicity (% non-Hispanic) | 95.9 | 98.2 |
| Disease duration in years (median/IQR) | 20 (15, 35) | 21 (15, 31) |
| Depression diagnosed or treated in past year (%) | 2 | 2.7 |
*Of the 272 subjects at visit 11, 54 actually met the criteria for focus with joint counts 0 or 1 and PGA >3, but of these only 49 had concurrent data on all symptoms. Some data not available in entire cohort.
BMI, body mass index; CRP, C reactive protein; DAS28, disease activity score in 28 joints; PGA, patient global assessment; SJC, swollen joint count; TJC, tender joint count.